. The surgical approach was laparoscopic in 57.3% patients, and open in 42.7% patients. Mean cost per discharge was significantly higher in open thoracic procedures compared to laparoscopic procedures, $24,995 vs. $19,238, respectively(pϽ0.001). Patients undergoing laparoscopic thoracic procedures had a significantly lower rate of surgical site infections compared to patients who underwent open procedures (4.8% vs. 5.8%, respectively, pϽ0.001). There was a significantly higher rate of blood transfusions with patients undergoing open surgery compared to patients undergoing laparoscopic procedures (13.2% vs. 6.3%, respectively, pϽ0.001). CONCLUSIONS: Laparoscopic thoracic procedures were associated with shorter hospital lengths of stay, lower rate of surgical site infections, hemorrhage, blood transfusion and mortality rates. The mean costs for laparoscopic procedures were significantly lower than mean costs for open procedures. These observations highlight the potential cost advantages of providing thoracic procedures through laparoscopic techniques as a method to potentially save increasingly scarce healthcare funds for hospitals. OBJECTIVES: Analyze the differential in selected direct costs of a collaborative structured blood glucose testing intervention in non-insulin treated patients with type 2 diabetes mellitus (T2DM) when compared to enhanced usual care (active control group (ACG)). METHODS: Data was derived from the Structured Testing Program (STeP) -a 1 year, prospective, cluster-randomized, multicenter study that examined the utility of a collaborative intervention using structured self-monitoring of blood glucose (SMBG) in 483 poorly-controlled (HbA1c Ͼ 7.5%) T2DM subjects compared to the ACG. The structured testing group (STG) used the ACCU-CHEK® 360¢ a View 3-day profile tool that facilitates collection and interpretation of 7-point glucose profiles. From a US payer perspective, direct costs of diabetes medications, lab HbA1c tests, physician visits, and blood glucose testing strips associated with STG were compared with ACG using student t-test at a significance level of 5%.
OBJECTIVES:
Analyze the differential in selected direct costs of a collaborative structured blood glucose testing intervention in non-insulin treated patients with type 2 diabetes mellitus (T2DM) when compared to enhanced usual care (active control group (ACG)). METHODS: Data was derived from the Structured Testing Program (STeP) -a 1 year, prospective, cluster-randomized, multicenter study that examined the utility of a collaborative intervention using structured self-monitoring of blood glucose (SMBG) in 483 poorly-controlled (HbA1c Ͼ 7.5%) T2DM subjects compared to the ACG. The structured testing group (STG) used the ACCU-CHEK® 360¢ a View 3-day profile tool that facilitates collection and interpretation of 7-point glucose profiles. From a US payer perspective, direct costs of diabetes medications, lab HbA1c tests, physician visits, and blood glucose testing strips associated with STG were compared with ACG using student t-test at a significance level of 5%.
RESULTS:
In the intent-to-treat population, STG showed a significantly greater HbA1c reduction over 12 months than the ACG (-1.2% vs. Ϫ0.9%; ⌬-0.3%; pϭ0.04). During the study, STG incurred ϩ$180.95 mean PPPY (Pay per Patient Year) total cost for diabetes medications, but -$173.73 mean PPPY for SMBG test strips, -$5.20 mean PPPY for lab HbA1c tests, and -$2.15 mean PPPY for physician visits compared to ACG. There was no significant difference in direct costs between STG and ACG (p ϭ0.9898). CONCLUSIONS: Use of a collaborative structured testing intervention improved HbA1c in STG without increasing direct cost. The increased STG medication cost was offset by a decreased use of blood glucose test strips. As previously reported, STG subjects performed significantly fewer tests/day than ACG subjects (mean ϭ 0.9 vs. 1.2, pϭ0.0003) over the year. Structured testing, from a 1 year US payer perspective, is an effective and overall cost-neutral tool for management of non-insulin treated patients with type 2 diabetes. 
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PMD19 COST-EFFECTIVENESS OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION TESTING IN THE SELECTION OF FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER IN ONTARIO
OBJECTIVES:
To assess the cost-effectiveness of epidermal growth factor receptor (EGFR) gene mutation testing for guiding the application of gefitinib as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) living in Ontario. METHODS: A decision analytic model was developed to compare EGFR gene mutation testing strategy versus no testing strategy in patients with advanced NSCLC. Under the testing strategy, patients tested positive for mutation would receive gefitinib as first-line therapy. Under no testing strategy, patients would receive conventional chemotherapy as first-line therapy. Probability variables were estimated through literature review. Utility variables were estimated from a multivariate linear regression analysis taking into account of the clinical responses and side-effects associated with treatment for NSCLC. Cost variables were based on two Ontario cost studies for NSCLC. Both benefits and costs were discounted at 5% per annum. RESULTS: Compared to no testing strategy, the incremental cost-effectiveness ratio for EGFR gene mutation testing was $46,021 per life year or $81,071 per quality adjusted life year (QALY). The cost-effectiveness of EGFR gene mutation testing was sensitive to the cost and efficacy of gefitinib. The budget impact analysis projected that EGFR gene mutation testing would cost Ontario health care system $4.6M, $7.0M, $7.9M, $8.1M, and $8.1M more a year in the next five years. CONCLUSIONS: EGFR gene mutation testing would not be costeffective in patients with advanced NSCLC in Ontario until willingness-to-pay was above $81,000 per QALY. The efficacy and cost of gefitinib significantly affected the cost-effectiveness of EGFR gene mutation testing. 
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